Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon | Zendy

Kevan L. Hartshorn | Zendy; Markus Vogt | Zendy; TingChao Chou | Zendy; Richard S. Blumberg | Zendy; Roy Byington | Zendy; Robert T. Schooley | Zendy; Martin Hirsch | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon

Author(s) -

Kevan L. Hartshorn,

Markus Vogt,

TingChao Chou,

Richard S. Blumberg,

Roy Byington,

Robert T. Schooley,

Martin Hirsch

Publication year - 1987

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.31.2.168

Subject(s) - recombinant dna , virology , in vitro , peripheral blood mononuclear cell , alpha interferon , interferon alfa , interferon , biology , virus , zidovudine , alpha (finance) , human immunodeficiency virus (hiv) , viral disease , toxicity , medicine , biochemistry , gene , construct validity , nursing , patient satisfaction

Both recombinant alpha A interferon and azidothymidine inhibit the replication of human immunodeficiency virus in peripheral blood mononuclear cells. Combinations of recombinant alpha A interferon and azidothymidine at concentrations that are easily achievable in patients synergistically inhibit human immunodeficiency virus in vitro with minimal toxicity. Combinations of antiretroviral compounds that act by different mechanisms may prove useful in the treatment of acquired immunodeficiency syndrome-related disorders.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research